CRISPR-Edited CD33-Negative Hematopoietic Cell Transplantation, a Target Shielding Technology Precisely Attacking Only Leukemic Cells: First Clinical Success of Combining CRISPR-Edited CD33-Negative Hematopoietic Cell Transplantation with ADC Gemtuzumab Ozogamicin Maintenance Therapy
##1. Critical Barrier to CD33-Targeted Therapy: Bone Marrow Toxicity In acute myeloid leukemia (AML) therapy, CD33 is a promising target, but administration of the antibody‑drug conjugate (ADC) gemtuzumab ozogamicin (GO) leads to severe bone marrow toxicity because it destroys not only tumor cells but also healthy hematopoietic stem cells that express CD33. Consequently, patients are exposed to life‑threatening anemia and infection risk during treatment, and clinicians are unable to increase drug dosage sufficiently, resulting in reduced therapeutic efficacy.
##2. Engineering a ‘Shield’ for Healthy Cells Using CRISPR‑Cas9 The research team devised an innovative strategy to pre‑emptively knock out the CD33 gene in donor hematopoietic stem cells using CRISPR‑Cas9. The resulting ‘CD33‑negative’ hematopoietic cells reconstitute a normal blood system after transplantation, yet, unlike malignant cells, they lack the CD33 target and therefore are intrinsically protected from subsequent administration of potent anti‑CD33 ADCs. This approach equips healthy cells with a genetic shield that fundamentally blocks drug‑induced toxicity.
##3. First-in-Human Clinical Success: Safe Engraftment and Anticancer Synergy Confirmed In the world’s first human trial of this approach, every patient who received the edited CD33‑negative hematopoietic cells achieved primary engraftment and restored stable hematologic parameters. Despite concurrent maintenance therapy with gemtuzumab ozogamicin, no severe bone‑marrow suppression or acute graft‑versus‑host disease (GVHD) – complications commonly observed with standard regimens – were reported. These findings provide definitive evidence that gene‑edited cells can safely coexist with a highly cytotoxic drug in vivo, enabling selective eradication of the tumor.
##4. Why it Matters: The Dawn of Next‑Generation Cell Therapies Based on ‘Target Shielding’ The significance of this study lies in expanding the purpose of gene‑editing from merely correcting defects to conferring resistance to therapeutic agents. By protecting hematopoietic stem cells, clinicians can now administer high‑dose targeted therapies that were previously untenable due to toxicity. This establishes a novel therapeutic paradigm—‘Target Shielding’—that not only applies to AML but also to other hematologic malignancies and, potentially, solid tumors, where cells lacking specific receptors are transplanted to dramatically broaden the scope of drug‑based treatment.
Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04362-1In a first-in-human trial combining the transplantation of CD33-negative CRISPR-edited hematopoietic cells with the CD33-targeted antibody–drug conjugate gemtuzumab ozogamicin, all transplanted patients achieved primary engraftment, and the treatment was well tolerated.
These data combine gene‑editing technology with an antibody‑drug conjugate (ADC) to pioneer a completely new clinical pathway of ‘selective cell protection.’ By circumventing the longstanding challenge of bone‑marrow toxicity through genetic programming, the work provides a concrete protocol that overcomes the limits of chemotherapy administration and maximizes patient survival, representing a disruptive academic and clinical advancement.